S
Steven Fakharzadeh
Researcher at Janssen Pharmaceutica
Publications - 43
Citations - 2539
Steven Fakharzadeh is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Ustekinumab & Psoriasis. The author has an hindex of 23, co-authored 42 publications receiving 2195 citations. Previous affiliations of Steven Fakharzadeh include University of Pennsylvania & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus
Joerg Albrecht,Lynne Taylor,Jesse A. Berlin,Samuel Dulay,Gina Ang,Steven Fakharzadeh,Jonathan Kantor,Ellen Kim,Giuseppe Militello,Karen S. McGinnis,Stephen K. Richardson,James R. Treat,Carmela C. Vittorio,Abby S. Van Voorhees,Victoria P. Werth +14 more
TL;DR: A measurement instrument for lupus erythematosus that could be used in clinical trials and which demonstrated clinical responsiveness needs to be evaluated in a prospective clinical trial, which is ongoing.
Journal ArticleDOI
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Robert E. Kalb,David Fiorentino,Mark Lebwohl,John Toole,Yves Poulin,Arnon D. Cohen,Kavitha Goyal,Steven Fakharzadeh,S. Calabro,Marc Chevrier,Wayne Langholff,Yin You,Craig L. Leonardi +12 more
TL;DR: Results from PSOLAR suggest a higher risk of serious infections with adalimumab and infliximab compared with nonmethotrexate and nonbiologic therapies.
Journal ArticleDOI
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Alan Menter,Kim A. Papp,Melinda Gooderham,David M. Pariser,Matthias Augustin,Francisco A. Kerdel,Steven Fakharzadeh,Kavitha Goyal,S. Calabro,Wayne Langholff,S. Chavers,D. Naessens,J. Sermon,Gerald G. Krueger +13 more
TL;DR: Drug survival is a marker for treatment sustainability in chronic diseases such as psoriasis and it is important to know whether the drug is still available for use in the future.
Journal ArticleDOI
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials
Kenneth B. Gordon,Kim A. Papp,Richard G. Langley,Vincent T. Ho,Alexa B. Kimball,Cynthia Guzzo,Newman Yeilding,Philippe Szapary,Steven Fakharzadeh,Shu Li,Ming Chun Hsu,Kristian Reich +11 more
TL;DR: The emerging safety profile of ustekinumab remains favorable and does not suggest increased rates of infection or malignancy through 3 years, as expected in the general US population.
Journal ArticleDOI
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
David Fiorentino,Vincent T. Ho,Mark Lebwohl,Luiz Leite,Lori Hopkins,Claudia Galindo,Kavitha Goyal,Wayne Langholff,Steven Fakharzadeh,Bhaskar Srivastava,Richard G. Langley +10 more
TL;DR: Long‐term treatment with a TNF‐&agr; inhibitor, but not methotrexate and ustekinumab, may increase risk for malignancy in patients with psoriasis.